Current practice in diagnosis and treatment of acute graft-versus-host disease: Results from a survey among german-austrian-swiss hematopoietic stem cell transplant centers

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 5, 2013, Pages 767-776

  Wolff, Daniel ^a   Ayuk, Francis ^b   Elmaagacli, Ahmet ^c   Bertz, Hartmut ^d   Lawitschka, Anita ^e   Schleuning, Michael ^f   Meyer, Ralf Georg ^g   Gerbitz, Armin ^h   Hilgendorf, Inken ⁱ   Hildebrandt, Gerhard C ^j   Edinger, Matthias ^a   Klein, Stephan ^k   Halter, Jörg ^l   Mousset, Sabine ^m   Holler, Ernst ^a   Greinix, Hildegard T ⁿ  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e ST ANNA CHILDREN S HOSPITAL   (Austria)

^f DKD   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER ROSTOCK   (Germany)

^j LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

^m GOETHE UNIVERSITY   (Germany)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

Acute graft versus host disease; Allogeneic hematopoietic stem cell transplantation; Immunosuppressive therapy

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BECLOMETASONE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; EVEROLIMUS; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; PSORALEN; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUSTRIA; CHOLESTASIS; CLINICAL PRACTICE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENDOSCOPY; ENGRAFTMENT; GASTROINTESTINAL DISEASE; GERMANY; GRAFT VERSUS HOST REACTION; HEALTH SURVEY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LAPAROSCOPY; LIVER BIOPSY; NAUSEA; PEDIATRIC HOSPITAL; PUVA; RASH; SALVAGE THERAPY; SKIN BIOPSY; STEROID THERAPY; SWITZERLAND; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ACUTE DISEASE; AUSTRIA; DATA COLLECTION; GERMANY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; SWITZERLAND; TREATMENT OUTCOME;

EID: 84876304695     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.018     Document Type: Article

References (111)

1. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
2. Chahal P., Levy C., Litzow M.R., Lindor K.D. Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol 2008, 23:222-225.
3. Iqbal M., Creger R.J., Fox R.M., et al. Laparoscopic liver biopsy to evaluate hepatic dysfunction in patients with hematologic malignancies: a useful tool to effect changes in management. Bone Marrow Transplant 1996, 17:655-662.
4. Jacobsohn D.A., Montross S., Anders V., Vogelsang G.B. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transplant 2001, 28:1047-1051.
5. Martin P.J., Rizzo J.D., Wingard J.R., et al. First and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012, 18:1150-1163.
6. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant 2005, 11:945-956.
7. Greinix H.T., Loddenkemper C., Pavletic S.Z., et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant 2011, 17:167-175.
8. Kreisel W., Dahlberg M., Bertz H., et al. Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transplant 2012, 47:430-438.
9. Ferrara J.L., Harris A.C., Greenson J.K., et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011, 118:6702-6708.
10. Shulman H.M., Sharma P., Amos D., et al. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 1988, 8:463-470.
11. Oshrine B., Lehmann L.E., Duncan C.N. Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2011, 33:e92-e97.
12. Kalambokis G., Manousou P., Vibhakorn S., et al. Transjugular liver biopsy-indications, adequacy, quality of specimens, and complications-a systematic review. J Hepatol 2007, 47:284-294.
13. Bacigalupo A., Van Lint M.T., Frassoni F., et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut 1983, 46:125-132.
14. Doney K.C., Weiden P.L., Storb R., Thomas E.D. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981, 11:1-8.
15. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
16. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76:1464-1472.
17. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990, 75:1024-1030.
18. Cahn J.Y., Bordigoni P., Tiberghien P., et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995, 60:939-942.
19. Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
20. Van Lint M.T., Uderzo C., Locasciulli A., et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998, 92:2288-2293.
21. Ruutu T., Hermans J., van Biezen A., et al. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998, 22:614-615.
22. Fried R.H., Murakami C.S., Fisher L.D., et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992, 116:624-629.
23. Ruutu T., Eriksson B., Remes K., et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002, 100:1977-1983.
24. Weisdorf D.J., Snover D.C., Haake R., et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990, 76:624-629.
25. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007, 109:4557-4563.
26. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
27. Uberti J.P., Ayash L., Ratanatharathorn V., et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:680-687.
28. Kennedy M.S., Deeg H.J., Storb R., et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. Am J Med 1985, 78:978-983.
29. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
30. Greinix H.T., Knobler R.M., Worel N., et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006, 91:405-408.
31. Diez-Campelo M., Sanchez-Guijo F.M., Perez-Simon J.A. Beclometasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease. Expert Opin Invest Drugs 2008, 17:1389-1401.
32. McDonald G.B., Bouvier M., Hockenbery D.M., et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998, 115:28-35.
33. Bertz H., Afting M., Kreisel W., et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999, 24:1185-1189.
34. Schnitzler M., Hasskarl J., Egger M., Bertz H., Finke J. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009, 15:910-918.
35. Schub N., Gunther A., Schrauder A., et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011, 46:143-147.
36. Martinez C., Solano C., Ferra C., et al. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biol Blood Marrow Transplant 2009, 15:639-642.
37. Pidala J., Kim J., Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:881-885.
38. Arora M., Nagaraj S., Witte J., et al. New classification of chronic GVHD: Added clarity from the consensus diagnoses. Bone Marrow Transplant 2009, 43:149-153.
39. Cho B.S., Min C.K., Eom K.S., et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009, 23:78-84.
40. Kuzmina Z., Eder S., Bohm A., et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 2012, 26:746-756.
41. Basara N., Blau W.I., Romer E., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998, 22:61-65.
42. Baudard M., Vincent A., Moreau P., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002, 30:287-295.
43. Krejci M., Doubek M., Buchler T., et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005, 84:681-685.
44. Xhaard A., Rocha V., Bueno B., et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant 2012, 18:406-413.
45. Pidala J., Kim J., Perkins J., et al. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant 2010, 45:919-924.
46. Furlong T., Martin P., Flowers M.E., et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009, 44:739-748.
47. Kim J.G., Sohn S.K., Kim D.H., et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004, 73:56-61.
48. Iida M., Fukuda T., Ikegame K., et al. Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan. Int J Hematol 2011, 93:523-531.
49. Calore E., Calo A., Tridello G., et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 2008, 42:421-425.
50. Dall'Amico R., Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002, 6:296-304.
51. Garban F., Drillat P., Makowski C., et al. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica 2005, 90:1096-1101.
52. Gonzalez-Vicent M., Ramirez M., Perez A., et al. Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. Haematologica 2008, 93:1278-1280.
53. Greinix H.T., Volc-Platzer B., Rabitsch W., et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998, 92:3098-3104.
54. Greinix H.T., Volc-Platzer B., Kalhs P., et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000, 96:2426-2431.
55. Kanold J., Merlin E., Halle P., et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007, 47:2276-2289.
56. Messina C., Locatelli F., Lanino E., et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122:118-127.
57. Perfetti P., Carlier P., Strada P., et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008, 42:609-617.
58. Perotti C., Del F.C., Tinelli C., et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010, 50:1359-1369.
59. Salvaneschi L., Perotti C., Zecca M., et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001, 41:1299-1305.
60. Greinix H.T., Worel N., Knobler R. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:1747-1748.
61. Hautmann A.H., Wolff D., Hahn J., et al. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System. Bone Marrow Transplant 2012, [In Press].
62. Busca A., Locatelli F., Marmont F., et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007, 82:45-52.
63. Hahn J., Erdmann A., Grube M., et al. High incidence of invasive aspergillosis after treatment of acute GvHD with the combination of OKT3 and infliximab. Bone Marrow Transplant 2001, 27:203.
64. Kavanaugh A., Keystone E.C. The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:S203-S208.
65. Knight D.M., Trinh H., Le J., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993, 30:1443-1453.
66. Scallon B.J., Moore M.A., Trinh H., et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251-259.
67. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649-654.
68. Kobbe G., Schneider P., Rohr U., et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNF-alpha antibody. Bone Marrow Transplant 2001, 28:47-49.
69. Nogueira M.C., Azevedo A.M., Pereira S.C., et al. Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease. Braz J Med Biol Res 2007, 40:1623-1629.
70. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004, 89:1352-1359.
71. Yamane T., Yamamura R., Aoyama Y., et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymph 2003, 44:2095-2097.
72. Jacobsohn D.A., Hallick J., Anders V., et al. Infliximab for steroid-refractory acute GVHD: A case series. Am J Hematol 2003, 74:119-124.
73. Sleight B.S., Chan K.W., Braun T.M., et al. Infliximab for GVHD therapy in children. Bone Marrow Transplant 2007, 40:473-480.
74. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102:2768-2776.
75. Motllo C., Ferra C., Lopez L., et al. [Salvage treatment with infliximab of steroid-resistant graft-versus-host disease in allogeneic transplanted patients]. Med Clin (Barc) 2011, 137:115-118.
76. Bolanos-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005, 23:2661-2668.
77. Klein S.A., Bug G., Mousset S., et al. Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin. Br J Haematol 2011, 154:143-146.
78. Schmitt T., Luft T., Hegenbart U., et al. Pentostatin for treatment of steroid-refractory acute GVHD: A retrospective single-center analysis. Bone Marrow Transplant 2011, 46:580-585.
79. Massenkeil G., Rackwitz S., Genvresse I., et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 30:899-903.
80. Schmidt-Hieber M., Fietz T., Knauf W., et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005, 130:568-574.
81. Funke V.A., de Medeiros C.R., Setubal D.C., et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006, 37:961-965.
82. Wang J.Z., Liu K.Y., Xu L.P., et al. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. Transplant Proc 2011, 43:1928-1933.
83. Lee S.J., Zahrieh D., Agura E., MacMillan M.L., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: Results of a randomized trial. Blood 2004, 104:1559-1564.
84. Carella A.M., Beltrami G., Scalzulli P.R., et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 2004, 33:131-132.
85. Gomez-Almaguer D., Ruiz-Arguelles G.J., del Carmen Tarin-Arzaga L., et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14:10-15.
86. Wandroo F., Auguston B., Cook M., et al. Successful use of campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant 2004, 34:285-287.
87. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001, 72:1924-1929.
88. Ghez D., Rubio M.T., Maillard N., et al. Rapamycin for refractory acute graft-versus-host disease. Transplantation 2009, 88:1081-1087.
89. Hoda D., Pidala J., Salgado-Vila N., et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2010, 45:1347-1351.
90. Rosenthal J., Pawlowska A., Bolotin E., et al. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer 2011, 57:142-146.
91. Arai S., Margolis J., Zahurak M., et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002, 8:155-160.
92. Ballesteros M., Ferra C., Serrano D., et al. Antithymocyte globulin therapy for steroid-resistant acute graft versus host disease. Am J Hematol 2008, 83:824-825.
93. Dugan M.J., Defor T.E., Steinbuch M., et al. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival. Ann Hematol 1997, 75:41-46.
94. Graziani F., Van Lint M.T., Dominietto A., et al. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica 2002, 87:973-978.
95. Khoury H., Kashyap A., Adkins D.R., et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001, 27:1059-1064.
96. MacMillan M.L., Weisdorf D.J., Davies S.M., et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:40-46.
97. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991, 77:1821-1828.
98. McCaul K.G., Nevill T.J., Barnett M.J., et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000, 9:367-374.
99. Remberger M., Aschan J., Barkholt L., et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001, 15:147-153.
100. Van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006, 107:4177-4181.
101. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
102. Roy J., McGlave P.B., Filipovich A.H., et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992, 10:77-82.
103. MacMillan M.L., Couriel D., Weisdorf D.J., et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007, 109:2657-2662.
104. Eppinger T., Ehninger G., Steinert M., et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990, 50:807-811.
105. Furlong T., Leisenring W., Storb R., et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:206-212.
106. Wiesmann A., Weller A., Lischka G., et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplant 1999, 23:151-155.
107. Wetzig T., Sticherling M., Simon J.C., et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005, 35:515-519.
108. Schlaak M., Schwind S., Wetzig T., et al. UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplant 2010, 45:1741-1748.
109. Grundmann-Kollmann M., Martin H., Ludwig R., et al. Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. Transplantation 2002, 74:1631-1634.
110. Feldstein J.V., Bolanos-Meade J., Anders V.L., Abuav R. Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin. J Am Acad Dermatol 2011, 65:733-738.
111. Vogelsang G. The doorstep to the temple of wisdom. Biol Blood Marrow Transplant 2011, 17:1417-1418.